SCHEMBL2002797

SCHEMBL2002797

O=C(O)C(CCCSc1ccccn1)N1C(=O)CCC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
PKM P14618 2/20 0.48
KMT2A Q03164 4/20 0.46
MAPT P10636 3/20 0.46
HPGD P15428 2/20 0.40
HSD17B10 Q99714 1/20 0.40
RAB9A P51151 8/20 0.40
SMN1; SMN2 Q16637 7/20 0.40
NPC1 O15118 7/20 0.40
MEN1 O00255 3/20 0.40
LMNA P02545 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 2/20 0.40
BLM P54132 1/20 0.38
CTDSP1 Q9GZU7 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
GRM2 Q14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21768790 0.93 ALDH1A1 (0.51) ALDH1A1PKMKMT2AMAPTHPGD
SCHEMBL3490799 0.88 ALDH1A1 (0.46) ALDH1A1PKMKMT2AMAPT
SCHEMBL616908 0.86 ALDH1A1 (0.54) ALDH1A1PKMKMT2AMAPTHPGD
SCHEMBL28851780 0.86 HPGD (0.55) ALDH1A1PKMKMT2AMAPTHPGD
SCHEMBL10340280 0.85 HDAC1 (0.47) ALDH1A1PKMKMT2AMAPT
SCHEMBL1752117 0.83 ALDH1A1 (0.48) ALDH1A1PKMKMT2AMAPTHPGD
Hydrogen Sulfide SCHEMBL20305480 0.82 ALDH1A1 (0.47) ALDH1A1PKMKMT2AMAPTHPGD
SCHEMBL10340551 0.81 ALDH1A1 (0.43) ALDH1A1PKMKMT2AMAPTHPGD
SCHEMBL28957076 0.79 LMNA (0.52) ALDH1A1PKMKMT2AMAPTHPGD
SCHEMBL44725 0.78 ALDH1A1 (0.50) ALDH1A1PKMKMT2AMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150175701-A1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2015-06-25 US disclosed
US-8906369-B2 Ovr110 antibody compositions and methods of use DIADEXUS, INC. (US) 2014-12-09 US disclosed
US-20130232589-A1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2013-09-05 US disclosed
US-8444971-B2 OVR110 antibody compositions and methods of use DIADEXUS, INC. (US) 2013-05-21 US disclosed
US-8354508-B2 PRO115 antibody compositions and methods of use DIADEXUS, INC. (US) 2013-01-15 US disclosed
US-8207311-B2 Ovr115 antibody compositions and methods of use DIADEXUS, INC. (US) 2012-06-26 US disclosed
US-8148093-B2 Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk DIADEXUS, INC. 2012-04-03 US disclosed
EP-1633784-B1 OVR110 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS INC (US) 2011-07-13 EP disclosed
US-20110159516-A1 PCan065 Antibody Compositions and Methods of Use DIADEXUS, INC. (US) 2011-06-30 US disclosed
US-7964195-B2 Using immunoglobulin which preferentially binds cancer specific antigen (OVR110) as treatment for head and neck or endometrial cancer DIADEXUS, INC. 2011-06-21 US disclosed
US-20100150907-A1 PRO115 ANTIBODY COMPOSITIONS AND METHODS OF USE DIADEXUS, INC. (US) 2010-06-17 US disclosed
US-20100136009-A1 OVR110 Antibody Compositions and Methods of Use DIAZYME LABORATORIES, INC. 2010-06-03 US disclosed
US-20070104647-A1 Ovr115 antibody compositions and methods of use DIAZYME LABORATORIES, INC. 2007-05-10 US disclosed